Figure 4.
Figure 4. Molecular response level versus imatinib mesylate treatment time. Shown is the cumulative percentage of patients achieving either a major molecular response (MMR; BCR-ABL mRNA log-drop ≥ 3) or a complete molecular response (CMR; undetected BCR-ABL mRNA).

Molecular response level versus imatinib mesylate treatment time. Shown is the cumulative percentage of patients achieving either a major molecular response (MMR; BCR-ABL mRNA log-drop ≥ 3) or a complete molecular response (CMR; undetected BCR-ABL mRNA).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal